Insulet Corporation

NasdaqGS:PODD Stock Report

Market Cap: US$17.1b

Insulet Valuation

Is PODD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of PODD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: PODD ($242.89) is trading below our estimate of future cash flow value ($294.98)

Significantly Below Future Cash Flow Value: PODD is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PODD?

Key metric: As PODD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PODD. This is calculated by dividing PODD's market cap by their current earnings.
What is PODD's PE Ratio?
PE Ratio69.2x
EarningsUS$247.10m
Market CapUS$17.10b

Price to Earnings Ratio vs Peers

How does PODD's PE Ratio compare to its peers?

The above table shows the PE ratio for PODD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.8x
PEN Penumbra
75x17.18%US$13.3b
ZBH Zimmer Biomet Holdings
26.6x16.60%US$19.2b
GMED Globus Medical
22.7x5.82%US$12.4b
HOLX Hologic
31.1x13.88%US$16.8b
PODD Insulet
69.2x23.10%US$17.1b

Price-To-Earnings vs Peers: PODD is expensive based on its Price-To-Earnings Ratio (69.2x) compared to the peer average (38.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does PODD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EMBC Embecta
4.1x5.68%US$575.02m
MHUA.F Meihua International Medical Technologies
0.8xn/aUS$7.61m
ADVB Advanced Biomed
1.5xn/aUS$5.81m
ARTH.Q Arch Therapeutics
n/an/aUS$4.00
No more companies available in this PE range
PODD 69.2xIndustry Avg. 29.4xNo. of Companies8PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PODD is expensive based on its Price-To-Earnings Ratio (69.2x) compared to the US Medical Equipment industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is PODD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PODD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio69.2x
Fair PE Ratio32.6x

Price-To-Earnings vs Fair Ratio: PODD is expensive based on its Price-To-Earnings Ratio (69.2x) compared to the estimated Fair Price-To-Earnings Ratio (32.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PODD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$242.89
US$354.40
+45.91%
9.50%US$435.00US$286.00n/a25
Feb ’27US$255.81
US$370.44
+44.81%
9.39%US$450.00US$274.00n/a25
Jan ’27US$284.24
US$377.72
+32.89%
7.21%US$450.00US$314.00n/a25
Dec ’26US$310.83
US$378.21
+21.68%
7.08%US$432.00US$314.00n/a24
Nov ’26US$313.01
US$363.63
+16.17%
6.89%US$415.00US$300.00n/a24
Oct ’26US$305.98
US$361.13
+18.02%
7.24%US$415.00US$300.00n/a23
Sep ’26US$339.88
US$353.39
+3.98%
7.19%US$400.00US$300.00n/a23
Aug ’26US$284.91
US$340.13
+19.38%
9.07%US$380.00US$260.00n/a23
Jul ’26US$299.99
US$336.01
+12.01%
10.11%US$380.00US$260.00n/a24
Jun ’26US$325.03
US$332.35
+2.25%
9.89%US$380.00US$260.00n/a23
May ’26US$250.25
US$313.60
+25.31%
7.38%US$350.00US$260.00n/a22
Apr ’26US$263.18
US$314.06
+19.33%
9.33%US$355.00US$234.00n/a23
Mar ’26US$272.27
US$312.88
+14.92%
9.41%US$355.00US$234.00US$246.6122
Feb ’26US$278.38
US$292.29
+5.00%
10.09%US$340.00US$234.00US$255.8122
Jan ’26US$261.07
US$286.99
+9.93%
10.41%US$340.00US$234.00US$284.2422
Dec ’25US$266.78
US$275.31
+3.20%
7.95%US$317.00US$234.00US$310.8322
Nov ’25US$235.61
US$247.99
+5.25%
9.31%US$285.00US$185.00US$313.0121
Oct ’25US$234.56
US$242.23
+3.27%
9.18%US$285.00US$185.00US$305.9821
Sep ’25US$202.77
US$236.85
+16.81%
7.37%US$264.00US$185.00US$339.8821
Aug ’25US$197.25
US$233.64
+18.45%
8.99%US$270.00US$185.00US$284.9121
Jul ’25US$196.16
US$233.64
+19.11%
8.99%US$270.00US$185.00US$299.9921
Jun ’25US$177.19
US$233.64
+31.86%
8.99%US$270.00US$185.00US$325.0321
May ’25US$170.27
US$236.27
+38.76%
7.03%US$270.00US$208.00US$250.2520
Apr ’25US$168.10
US$236.13
+40.47%
7.04%US$270.00US$208.00US$263.1820
Mar ’25US$169.25
US$236.77
+39.89%
7.64%US$270.00US$208.00US$272.2720
US$354.4
Fair Value
31.5% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/05 08:51
End of Day Share Price 2026/03/04 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insulet Corporation is covered by 46 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Travis SteedBarclays
Matthew MiksicBarclays